Virtual Clinical Trials Market
Virtual Clinical Trials Market Report 2024-2029 - Breaking Down Barriers in Women's Health Clinical Studies
September 16, 2024 08:37 ET | Research and Markets
Dublin, Sept. 16, 2024 (GLOBE NEWSWIRE) -- The "Virtual Clinical Trials Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.The Virtual Clinical Trials...
PharmAla Biotech Logo 800 x 422.png
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
September 11, 2024 08:55 ET | PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
Clinical ink announc
Clinical ink announces EDCXtra™: An integrated web-based EDC, DDC and eCOA platform
August 29, 2024 11:36 ET | Clinical Ink
Winston Salem, NC, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, announced the launch of EDCXtraTM, an innovative Electronic Data Capture (EDC) system. ...
LAC
Key Highlights of Lighthouse Fusion
August 27, 2024 09:00 ET | Lighthouse Autism Center
Lighthouse Autism Center expands its speech therapy program with more dually certified SLPs and BCBAs, offering better outcomes for children with autism.
PharmAla Biotech Logo 800 x 422.png
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024 18:18 ET | PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
Compass-logo-RGB-outlines.png
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
August 07, 2024 08:00 ET | Compass Therapeutics
BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass-logo-RGB-outlines.png
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
August 06, 2024 08:00 ET | Compass Therapeutics
Completed enrollment of the planned 150 patients in COMPANION-002, a Phase 2/3 trial of CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced Metastatic...
HeartFlow Logo.png
SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography
July 16, 2024 12:00 ET | HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will be presenting new findings on...
Full Logo - OKYO .jpg
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
July 11, 2024 07:00 ET | OKYO Pharma LTD
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
July 08, 2024 16:05 ET | Kymera Therapeutics, Inc.
WATERTOWN, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...